Depemokimab Clinical Trials (2026): 13 Studies for Asthma & Pulmonary Disease, Chronic Obstructive
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
13 Depemokimab clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 5 indications (including Asthma & Pulmonary Disease, Chronic Obstructive) and 7,462 total planned enrollment. 12 Phase 3 Depemokimab trials are listed. 6 Depemokimab clinical trials are actively recruiting at 76 U.S. sites across 25 states. Most recent activity: NCT07456033 (Jul 2030).
Where to Participate: All Depemokimab Trial Sites in the U.S. (76 sites across 25 states)
Every actively recruiting Depemokimabtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| AL | GSK Investigational Site | Sheffield35660 | NCT06961214 | Map |
| CA | GSK Investigational Site | San Diego920237 | NCT05334368 | Map |
| CO | GSK Investigational Site | Aurora80012 | NCT06961214 | Map |
| FL | GSK Investigational Site | Brooksville346135 | NCT06961214 | Map |
| FL | GSK Investigational Site | Brooksville34613 | NCT06979323 | Map |
| FL | GSK Investigational Site | Doral33172 | NCT06961214 | Map |
| FL | GSK Investigational Site | Doral33172 | NCT07177339 | Map |
| FL | GSK Investigational Site | Fort Lauderdale33316 | NCT06961214 | Map |
| FL | GSK Investigational Site | Loxahatchee Groves33470 | NCT06959095 | Map |
| FL | GSK Investigational Site | Miami33155 | NCT06959095 | Map |
| FL | GSK Investigational Site | Miami33122 | NCT06961214 | Map |
| FL | GSK Investigational Site | Miami33125 | NCT06961214 | Map |
| FL | GSK Investigational Site | Miami33155 | NCT06961214 | Map |
| FL | GSK Investigational Site | Miami33165 | NCT06961214 | Map |
| FL | GSK Investigational Site | Miami33175 | NCT06961214 | Map |
| FL | GSK Investigational Site | Miami33176 | NCT06961214 | Map |
| FL | GSK Investigational Site | Miami33176 | NCT06961214 | Map |
| FL | GSK Investigational Site | Miami Lakes33016 | NCT06961214 | Map |
| FL | GSK Investigational Site | Naples34102 | NCT06961214 | Map |
| FL | GSK Investigational Site | New Port Richey34653 | NCT06961214 | Map |
| FL | GSK Investigational Site | Ocala34471 | NCT06961214 | Map |
| FL | GSK Investigational Site | Orlando32825 | NCT06961214 | Map |
| FL | GSK Investigational Site | Ormond Beach32174 | NCT06961214 | Map |
| FL | GSK Investigational Site | Palmetto Bay33157 | NCT06961214 | Map |
| FL | GSK Investigational Site | Plantation33324 | NCT06979323 | Map |
| FL | GSK Investigational Site | St. Petersburg33704 | NCT06961214 | Map |
| GA | GSK Investigational Site | Adairsville30103 | NCT06961214 | Map |
| GA | GSK Investigational Site | Atlanta30322 | NCT05334368 | Map |
| GA | GSK Investigational Site | Cordele31015 | NCT06961214 | Map |
| GA | GSK Investigational Site | East Point30344 | NCT06961214 | Map |
| GA | GSK Investigational Site | Morrow30260 | NCT06961214 | Map |
| ID | GSK Investigational Site | Boise83702 | NCT06961214 | Map |
| IL | GSK Investigational Site | Chicago60608 | NCT06961214 | Map |
| KS | GSK Investigational Site | Kansas City66160 | NCT06979323 | Map |
| LA | GSK Investigational Site | Baton Rouge70816 | NCT06961214 | Map |
| LA | GSK Investigational Site | Lafayette70506 | NCT06961214 | Map |
| LA | GSK Investigational Site | Shreveport71105 | NCT06961214 | Map |
| ME | GSK Investigational Site | Bangor04401 | NCT06961214 | Map |
| MD | GSK Investigational Site | Rockville20854 | NCT06961214 | Map |
| MA | GSK Investigational Site | Boston02111 | NCT05334368 | Map |
| MI | GSK Investigational Site | Allen Park48101 | NCT06961214 | Map |
| MI | GSK Investigational Site | Detroit48202 | NCT06961214 | Map |
| MI | GSK Investigational Site | Garden City48135 | NCT06961214 | Map |
| MI | GSK Investigational Site | Troy48085 | NCT06961214 | Map |
| MO | GSK Investigational Site | St Louis63110 | NCT06979323 | Map |
| NV | GSK Investigational Site | Las Vegas89144 | NCT06961214 | Map |
| NJ | GSK Investigational Site | Moorestown08057 | NCT06961214 | Map |
| NJ | GSK Investigational Site | New Brunswick08901 | NCT06979323 | Map |
| NJ | GSK Investigational Site | Sewell08080 | NCT06961214 | Map |
| NY | GSK Investigational Site | Mount Kisco10549 | NCT06961214 | Map |
| NY | GSK Investigational Site | New Windsor12553 | NCT06961214 | Map |
| NY | GSK Investigational Site | New York10029 | NCT06979323 | Map |
| NC | GSK Investigational Site | Shelby28152 | NCT06961214 | Map |
| OH | GSK Investigational Site | Cincinnati45229 | NCT05334368 | Map |
| OH | GSK Investigational Site | Columbus43212 | NCT05334368 | Map |
| PA | GSK Investigational Site | DuBois15801 | NCT06961214 | Map |
| PA | GSK Investigational Site | DuBois15801 | NCT06979323 | Map |
| PA | GSK Investigational Site | Philadelphia19140 | NCT06961214 | Map |
| PA | GSK Investigational Site | Philadelphia19140-5103 | NCT06979323 | Map |
| SC | GSK Investigational Site | Charleston29425 | NCT05334368 | Map |
| SC | GSK Investigational Site | Rock Hill29732 | NCT06959095 | Map |
| SC | GSK Investigational Site | Spartanburg29303 | NCT06961214 | Map |
| SC | GSK Investigational Site | Union29379 | NCT06961214 | Map |
| TN | GSK Investigational Site | Knoxville37919 | NCT06961214 | Map |
| TX | GSK Investigational Site | Austin78744 | NCT06961214 | Map |
| TX | GSK Investigational Site | Corsicana75110 | NCT06959095 | Map |
| TX | GSK Investigational Site | Dallas75254 | NCT06961214 | Map |
| TX | GSK Investigational Site | El Paso79902-1123 | NCT06961214 | Map |
| TX | GSK Investigational Site | Houston77094 | NCT06961214 | Map |
| TX | GSK Investigational Site | Lampasas76550 | NCT06961214 | Map |
| TX | GSK Investigational Site | McKinney75069 | NCT06979323 | Map |
| TX | GSK Investigational Site | Richmond77407 | NCT06961214 | Map |
| TX | GSK Investigational Site | San Antonio78229 | NCT06961214 | Map |
| TX | GSK Investigational Site | Webster77598 | NCT06961214 | Map |
| UT | GSK Investigational Site | Salt Lake City84132 | NCT05334368 | Map |
| WV | GSK Investigational Site | Morgantown26505-0423 | NCT06961214 | Map |
Depemokimab clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | completed | not yet recruiting | Total |
|---|---|---|---|---|---|
| P1 | 1 | 1 | |||
| P3 | 5 | 1 | 5 | 1 | 12 |
Recruiting Depemokimab clinical trials (6)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07456033 | MODIFYA Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma | P3 | Asthma | 456 | Mar 2026 |
| NCT07177339 | VIGILANTeValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation | P3 | Pulmonary Disease, Chronic Obstructive | 1,196 | Oct 2025 |
| NCT06961214 | ENDURA-2Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2) | P3 | Pulmonary Disease, Chronic Obstructive | 960 | Jun 2025 |
| NCT06959095 | ENDURA -1Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1) | P3 | Pulmonary Disease, Chronic Obstructive | 981 | Jun 2025 |
| NCT05334368 | DESTINYDepemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial | P3 | Hypereosinophilic Syndrome | 123 | Sep 2022 |
| NCT06979323 | Depemokimab Asthma Imaging and Bronchoscopy Sub-Study | P3 | Asthma | 150 | Jun 2025 |
Depemokimab clinical trials by indication
Asthma (6)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07456033 | MODIFY | P3 | not yet recruiting | A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma |
| NCT06979323 | — | P3 | recruiting | Depemokimab Asthma Imaging and Bronchoscopy Sub-Study |
| NCT04718389 | NIMBLE | P3 | completed | A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype |
| NCT05243680 | AGILE | P3 | completed | An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103) |
| NCT04719832 | SWIFT-1 | P3 | completed | Placebo-controlled Efficacy and Safety Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype |
| NCT05602025 | PK | P1 | completed | A Study to Compare the Pharmacokinetics (PK) of Depemokimab When Delivered With a Safety Syringe Device (SSD) or an Autoinjector in Healthy Adult Participants |
Pulmonary Disease, Chronic Obstructive (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07177339 | VIGILANT | P3 | recruiting | eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation |
| NCT06961214 | ENDURA-2 | P3 | recruiting | Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2) |
| NCT06959095 | ENDURA -1 | P3 | recruiting | Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1) |
Nasal Polyps (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05274750 | ANCHOR-1 | P3 | completed | Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps |
| NCT05281523 | ANCHOR-2 | P3 | completed | Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps (ANCHOR-2) |
Hypereosinophilic Syndrome (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05334368 | DESTINY | P3 | recruiting | Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial |
Eosinophilic Granulomatosis With Polyangiitis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05263934 | OCEAN | P3 | active not recruiting | Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA) |
Depemokimab pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| MODIFY | NCT07456033 | P3 | not yet recruiting | Asthma | 456 | — |
| VIGILANT | NCT07177339 | P3 | recruiting | Pulmonary Disease, Chronic Obstructive | 1,196 | — |
| ENDURA-2 | NCT06961214 | P3 | recruiting | Pulmonary Disease, Chronic Obstructive | 960 | — |
| ENDURA -1 | NCT06959095 | P3 | recruiting | Pulmonary Disease, Chronic Obstructive | 981 | — |
| DESTINY | NCT05334368 | P3 | recruiting | Hypereosinophilic Syndrome | 123 | — |
| OCEAN | NCT05263934 | P3 | active not recruiting | Eosinophilic Granulomatosis With Polyangiitis | 163 | — |
| NIMBLE | NCT04718389 | P3 | completed | Asthma | 1,717 | — |
| AGILE | NCT05243680 | P3 | completed | Asthma | 641 | — |
| ANCHOR-1 | NCT05274750 | P3 | completed | Nasal Polyps | 276 | — |
| ANCHOR-2 | NCT05281523 | P3 | completed | Nasal Polyps | 264 | — |
| SWIFT-1 | NCT04719832 | P3 | completed | Asthma | 395 | — |
All Depemokimab trials (13)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07456033 | MODIFY | A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma | P3 | not yet recruiting | 456 | GlaxoSmithKline | Mar 2026 |
| NCT07177339 | VIGILANT | eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation | P3 | recruiting | 1,196 | GlaxoSmithKline | Oct 2025 |
| NCT06961214 | ENDURA-2 | Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2) | P3 | recruiting | 960 | GlaxoSmithKline | Jun 2025 |
| NCT06959095 | ENDURA -1 | Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1) | P3 | recruiting | 981 | GlaxoSmithKline | Jun 2025 |
| NCT05334368 | DESTINY | Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial | P3 | recruiting | 123 | GlaxoSmithKline | Sep 2022 |
| NCT06979323 | Depemokimab Asthma Imaging and Bronchoscopy Sub-Study | P3 | recruiting | 150 | GlaxoSmithKline | Jun 2025 | |
| NCT05263934 | OCEAN | Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA) | P3 | active not recruiting | 163 | GlaxoSmithKline | Jul 2022 |
| NCT04718389 | NIMBLE | A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype | P3 | completed | 1,717 | GlaxoSmithKline | Jan 2021 |
| NCT05243680 | AGILE | An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103) | P3 | completed | 641 | GlaxoSmithKline | Mar 2022 |
| NCT05274750 | ANCHOR-1 | Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps | P3 | completed | 276 | GlaxoSmithKline | Apr 2022 |
| NCT05281523 | ANCHOR-2 | Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps (ANCHOR-2) | P3 | completed | 264 | GlaxoSmithKline | Apr 2022 |
| NCT04719832 | SWIFT-1 | Placebo-controlled Efficacy and Safety Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype | P3 | completed | 395 | GlaxoSmithKline | Mar 2021 |
| NCT05602025 | PK | A Study to Compare the Pharmacokinetics (PK) of Depemokimab When Delivered With a Safety Syringe Device (SSD) or an Autoinjector in Healthy Adult Participants | P1 | completed | 140 | GlaxoSmithKline | Dec 2022 |
Depemokimab clinical trials: frequently asked questions
- How many Depemokimab clinical trials are there?
- 13 Depemokimab clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 5 are actively recruiting participants. 6 are marked completed.
- Are Depemokimab clinical trials recruiting in 2026?
- Yes — 5 Depemokimab trials are actively recruiting in 2026, with 76 U.S. sites across 25 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Depemokimab being studied for?
- Depemokimab is being studied for Asthma, Pulmonary Disease, Chronic Obstructive, Nasal Polyps, Eosinophilic Granulomatosis With Polyangiitis, Hypereosinophilic Syndrome. The trials are grouped by indication on this page.
- What phase is Depemokimab in?
- Depemokimab clinical trials span 12 Phase 3, 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Depemokimab clinical trials?
- The lead sponsor across the most Depemokimab trials is GlaxoSmithKline. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Depemokimabas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: